Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.

Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA.

Eur J Cancer. 2019 Nov;121:177-183. doi: 10.1016/j.ejca.2019.08.015. Epub 2019 Oct 3.

PMID:
31586757
2.

Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN).

Massett HA, Mishkin G, Moscow JA, Gravell A, Steketee M, Kruhm M, Han SH, Barry B, Montello M, Zwiebel J, Abrams JS, Doroshow JH, Ivy SP.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-1754. [Epub ahead of print]

PMID:
31439585
3.

Future Approaches to Precision Oncology-Based Clinical Trials.

Mittra A, Moscow JA.

Cancer J. 2019 Jul/Aug;25(4):300-304. doi: 10.1097/PPO.0000000000000383.

PMID:
31335395
4.

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.

Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT.

Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17.

PMID:
31097774
5.

Distinguishing mechanisms of adverse drug reactions from mechanisms of actions of drugs.

Wu TH, Karim N, Moscow JA.

Oncotarget. 2018 Aug 21;9(65):32404-32405. doi: 10.18632/oncotarget.25968. eCollection 2018 Aug 21. No abstract available.

6.

The evidence framework for precision cancer medicine.

Moscow JA, Fojo T, Schilsky RL.

Nat Rev Clin Oncol. 2018 Mar;15(3):183-192. doi: 10.1038/nrclinonc.2017.186. Epub 2017 Dec 19. Review.

PMID:
29255239
7.

Steps forward for cancer precision medicine.

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty.

Nat Rev Drug Discov. 2018 Jan;17(1):1-2. doi: 10.1038/nrd.2017.218. Epub 2017 Nov 24.

PMID:
29170471
8.

Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury.

Yarana C, Carroll D, Chen J, Chaiswing L, Zhao Y, Noel T, Alstott M, Bae Y, Dressler EV, Moscow JA, Butterfield DA, Zhu H, St Clair DK.

Clin Cancer Res. 2018 Apr 1;24(7):1644-1653. doi: 10.1158/1078-0432.CCR-17-2046. Epub 2017 Oct 25.

9.

Societal challenges of precision medicine: Bringing order to chaos.

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty.

Eur J Cancer. 2017 Oct;84:325-334. doi: 10.1016/j.ejca.2017.07.028. Epub 2017 Sep 4.

PMID:
28865260
10.

Superoxide induces protein oxidation in plasma and TNF-α elevation in macrophage culture: Insights into mechanisms of neurotoxicity following doxorubicin chemotherapy.

Keeney JT, Miriyala S, Noel T, Moscow JA, St Clair DK, Butterfield DA.

Cancer Lett. 2015 Oct 28;367(2):157-61. doi: 10.1016/j.canlet.2015.07.023. Epub 2015 Jul 28.

11.

Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study.

Hayslip J, Dressler EV, Weiss H, Taylor TJ, Chambers M, Noel T, Miriyala S, Keeney JT, Ren X, Sultana R, Vore M, Butterfield DA, St Clair D, Moscow JA.

PLoS One. 2015 Apr 24;10(4):e0124988. doi: 10.1371/journal.pone.0124988. eCollection 2015.

12.

Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis.

Brohl AS, Stinson JR, Su HC, Badgett T, Jennings CD, Sukumar G, Sindiri S, Wang W, Kardava L, Moir S, Dalgard CL, Moscow JA, Khan J, Snow AL.

J Clin Immunol. 2015 Jan;35(1):32-46. doi: 10.1007/s10875-014-0106-4. Epub 2014 Oct 29.

13.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA.

Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. doi: 10.1002/pbc.25117. Epub 2014 Jun 29.

14.

Selectivity and potency of microcystin congeners against OATP1B1 and OATP1B3 expressing cancer cells.

Niedermeyer TH, Daily A, Swiatecka-Hagenbruch M, Moscow JA.

PLoS One. 2014 Mar 10;9(3):e91476. doi: 10.1371/journal.pone.0091476. eCollection 2014.

15.

Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells.

Liu S, Miriyala S, Keaton MA, Jordan CT, Wiedl C, Clair DK, Moscow JA.

PLoS One. 2014 Jan 15;9(1):e85702. doi: 10.1371/journal.pone.0085702. eCollection 2014.

16.
17.

Low-thiamine diet increases mammary tumor latency in FVB/N-Tg(MMTVneu) mice.

Daily A, Liu S, Bhatnagar S, Karabakhtsian RG, Moscow JA.

Int J Vitam Nutr Res. 2012 Aug;82(4):298-302. doi: 10.1024/0300-9831/a000122.

PMID:
23591667
18.

Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.

Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP.

Br J Haematol. 2013 May;161(3):406-10. doi: 10.1111/bjh.12268. Epub 2013 Feb 23.

PMID:
23432727
19.

Pharmacologic properties of polyethylene glycol-modified Bacillus thiaminolyticus thiaminase I enzyme.

Liu S, Bae Y, Leggas M, Daily A, Bhatnagar S, Miriyala S, St Clair DK, Moscow JA.

J Pharmacol Exp Ther. 2012 Jun;341(3):775-83. doi: 10.1124/jpet.112.191817. Epub 2012 Mar 19.

PMID:
22431205
20.

Linear chain PEGylated recombinant Bacillus thiaminolyticus thiaminase I enzyme has growth inhibitory activity against lymphoid leukemia cell lines.

Daily A, Liu S, Bae Y, Bhatnagar S, Moscow JA.

Mol Cancer Ther. 2011 Sep;10(9):1563-70. doi: 10.1158/1535-7163.MCT-11-0003. Epub 2011 Jun 22.

21.

Configuration and rearrangement of the human GAGE gene clusters.

Killen MW, Taylor TL, Stults DM, Jin W, Wang LL, Moscow JA, Pierce AJ.

Am J Transl Res. 2011 May 15;3(3):234-42. Epub 2011 May 8.

22.

2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain.

Aluise CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, Taylor TJ, Cai J, Pierce WM, Vore M, Moscow JA, St Clair DK, Butterfield DA.

Free Radic Biol Med. 2011 Jun 1;50(11):1630-8. doi: 10.1016/j.freeradbiomed.2011.03.009. Epub 2011 Mar 21.

PMID:
21421044
23.

Can an enzyme cofactor be a factor in malignant progression?

Richardson AD, Moscow JA.

Cancer Biol Ther. 2010 Dec 1;10(11):1112-4. Epub 2010 Dec 1. No abstract available.

PMID:
21099372
24.

Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction.

Aluise CD, Sultana R, Tangpong J, Vore M, St Clair D, Moscow JA, Butterfield DA.

Adv Exp Med Biol. 2010;678:147-56. Review.

PMID:
20738017
25.

Addressing the design of in vitro models for the investigation of microcystins: the essential role of transporter-mediated uptake.

Monks NR, Moscow JA.

Cell Biol Int. 2010 Sep;34(9):907-9. doi: 10.1042/CBI20100244.

PMID:
20491673
26.

A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.

Arnold SM, Rinehart JJ, Tsakalozou E, Eckardt JR, Fields SZ, Shelton BJ, DeSimone PA, Kee BK, Moscow JA, Leggas M.

Clin Cancer Res. 2010 Jan 15;16(2):673-80. doi: 10.1158/1078-0432.CCR-09-2429. Epub 2010 Jan 12.

27.

Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition.

Daily A, Monks NR, Leggas M, Moscow JA.

Toxicon. 2010 Apr 1;55(4):827-37. doi: 10.1016/j.toxicon.2009.11.019. Epub 2009 Nov 24.

PMID:
19944114
28.

Human rRNA gene clusters are recombinational hotspots in cancer.

Stults DM, Killen MW, Williamson EP, Hourigan JS, Vargas HD, Arnold SM, Moscow JA, Pierce AJ.

Cancer Res. 2009 Dec 1;69(23):9096-104. doi: 10.1158/0008-5472.CAN-09-2680. Epub 2009 Nov 17.

29.

Sensitivity of breast cancer cell lines to recombinant thiaminase I.

Liu S, Monks NR, Hanes JW, Begley TP, Yu H, Moscow JA.

Cancer Chemother Pharmacol. 2010 May;66(1):171-9. doi: 10.1007/s00280-009-1148-9. Epub 2009 Oct 15.

30.

Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.

D'Orazio JA, Pulliam JF, Moscow JA.

Pediatr Hematol Oncol. 2008 Jun;25(5):457-68. doi: 10.1080/08880010802104494.

PMID:
18569848
31.
32.

Transfusion management strategies: a survey of practicing pediatric hematology/oncology specialists.

Wong EC, Perez-Albuerne E, Moscow JA, Luban NL.

Pediatr Blood Cancer. 2005 Feb;44(2):119-27.

PMID:
15452914
33.

NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.

Ding Y, Tong M, Liu S, Moscow JA, Tai HH.

Carcinogenesis. 2005 Jan;26(1):65-72. Epub 2004 Sep 9.

PMID:
15358636
35.

A survey of clinical productivity and current procedural terminology (CPT) coding patterns of pediatric hematologist/oncologists.

Griffin TC, Hutter JJ, Johnson KK, Moscow JA.

Pediatr Blood Cancer. 2004 Aug;43(2):140-7.

PMID:
15236280
36.

Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.

Levy AS, Sather HN, Steinherz PG, Sowers R, La M, Moscow JA, Gaynon PS, Uckun FM, Bertino JR, Gorlick R; Children's Cancer Group Study.

J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95.

PMID:
12972803
37.

Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis.

Liu S, Huang H, Lu X, Golinski M, Comesse S, Watt D, Grossman RB, Moscow JA.

Mol Cancer Res. 2003 Jul;1(9):665-73.

38.

Basolateral active uptake of nitrofurantoin in the CIT3 cell culture model of lactation.

Gerk PM, Moscow JA, McNamara PJ.

Drug Metab Dispos. 2003 Jun;31(6):691-3.

PMID:
12756197
39.

Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters.

Oyewumi MO, Liu S, Moscow JA, Mumper RJ.

Bioconjug Chem. 2003 Mar-Apr;14(2):404-11.

PMID:
12643751
40.

Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy.

Dishop MK, Warner BW, Dehner LP, Kriss VM, Greenwood MF, Geil JD, Moscow JA.

J Pediatr Hematol Oncol. 2003 Feb;25(2):153-8. Review.

PMID:
12571469
41.

Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity.

Lu X, Gong S, Monks A, Zaharevitz D, Moscow JA.

J Exp Ther Oncol. 2002 Jul-Aug;2(4):200-12.

PMID:
12416024
42.

The murine-reduced folate carrier gene can act as a selectable marker and a suicide gene in hematopoietic cells in vivo.

Liu S, Song L, Bevins R, Birhiray O, Moscow JA.

Hum Gene Ther. 2002 Sep 20;13(14):1777-82.

PMID:
12396629
43.
44.

Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias.

Gong S, Lu X, Xu Y, Swiderski CF, Jordan CT, Moscow JA.

Exp Hematol. 2002 Oct;30(10):1162-9.

PMID:
12384147
45.
46.

Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk.

Gerk PM, Oo CY, Paxton EW, Moscow JA, McNamara PJ.

J Pharmacol Exp Ther. 2001 Jan;296(1):175-80.

PMID:
11123378
47.

Langerhans cell histiocytosis after therapy for a malignant germ cell tumor of the central nervous system.

Hale GA, Greenwood MF, Geil JD, Moscow JA.

J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):355-7.

PMID:
10959908
48.

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A.

Clin Cancer Res. 1999 Jul;5(7):1619-28.

49.

Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy.

Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, Chow C, Venzon D, Sorrentino B, Chiang Y, Goldspiel B, Leitman S, Read EJ, Abati A, Gottesman MM, Pastan I, Sellers S, Dunbar C, Cowan KH.

Blood. 1999 Jul 1;94(1):52-61.

PMID:
10381498
50.

Supplemental Content

Loading ...
Support Center